NEWM&A

Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal

Published on 4/1/2026

#APLS#M&A#CantorFitzgerald#Biogen
Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal

AI Summary

Cantor Fitzgerald has downgraded Apellis Pharmaceuticals (APLS) following Biogen's recent acquisition. This decision reflects potential market implications for APLS shares amidst Biogen's active strategic moves. The downgrade is a response to shifts in market sentiment influenced by M&A activities. Investors may want to monitor how this impacts APLS's trading volumes and price movements in the near term.

Source: Read original article (opens in new tab)

Related News

TruBridge (TRUB) Stock Rated Overweight at $25 by Cantor Fitzgerald
Markets

TruBridge (TRUB) Stock Rated Overweight at $25 by Cantor Fitzgerald

Apr 1

Ascendis Pharma (ASND) Stock Rating Reiterated as Overweight by Cantor Fitzgerald
Markets

Ascendis Pharma (ASND) Stock Rating Reiterated as Overweight by Cantor Fitzgerald

Apr 1

Raiders (LV) Sale Approved at $11 Billion Valuation for 3.5% Stake
M&A

Raiders (LV) Sale Approved at $11 Billion Valuation for 3.5% Stake

Apr 1

Fidelity (FDBC) to acquire Affinity Bancshares for $142.8 million
M&A

Fidelity (FDBC) to acquire Affinity Bancshares for $142.8 million

Apr 1